2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Molecular Testing, Serologic Tests, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult
PAPER

2200 Racial variation in serum free light chain measurements and implications for monoclonal gammopathy screening: A retrospective analysis

Audrey Harris, MD, Vasu Bansal, MBBS2, Aakriti Adhikari, MD3, Chitramalya Dan, MD4, Sheshadri Madhusudhana, MD5
1 University Of Missouri Kansas City, Kansas City, Missouri, United States
2 University Of Missouri Kansas City, Kansas City, Missouri, United States
3 University Of Missouri Kansas City, Kansas City, Missouri, United States
4 University Of Missouri Kansas City, Kansas City, Missouri, United States
5 University Of Missouri Kansas City, Kansas City, Missouri, United States

Introduction

Current serum free light chain (FLC) reference intervals are derived predominantly from White populations and may not accurately reflect biologic variation across diverse racial groups. This may contribute to false-positive abnormal FLC ratios and overdiagnosis of light chain monoclonal gammopathy of undetermined significance (LC-MGUS). We evaluated racial differences in serum κ (kappa), λ (lambda), and κ/λ FLC ratio (FLCr) among adults without evidence of monoclonal gammopathy or renal dysfunction.

Methods

We performed a retrospective study of adults (≥18 years) who underwent serum FLC testing at University Health between January 2015 and December 2025. Patients with abnormal serum protein electrophoresis, estimated glomerular filtration rate below the normal range, or a prior diagnosis of multiple myeloma or another lymphoproliferative disorder were excluded. For patients with multiple FLC measurements, a single observation per patient was retained. Continuous variables were summarized using medians and central 95% reference intervals (2.5th-97.5th percentiles). Comparisons among racial groups were performed using the Kruskal-Wallis test with pairwise Black-versus-White comparisons using the Mann-Whitney U test, consistent with contemporary reference interval methodology.

Results

A total of 2,727 patients met inclusion criteria. The cohort included 1,279 (46.9%) Black, 913 (33.5%) White, 306 (11.2%) individuals of other races, and 54 (2.0%) Asian individuals. Significant differences were observed across racial groups for κ FLC (P=1.55×10^-15), λ FLC (P=2.85×10^-12), and FLCr (P=3.49×10^-15). Black individuals demonstrated higher median κ concentrations than White individuals (50.2 vs 37.2 mg/L; P=2.84×10^-16), higher λ concentrations (30.3 vs 25.0 mg/L; P=1.71×10^-9), and higher FLCr (1.58 vs 1.41; P=5.18×10^-14). Median κ concentrations were approximately 35% higher, λ concentrations 21% higher, and FLCr 12% higher among Black individuals. Race-specific reference interval estimation demonstrated broader upper limits among Black individuals for κ (11.5-433.9 vs 10.2-248.4 mg/L), λ (8.7-274.0 vs 7.6-158.5 mg/L), and FLCr (0.49-7.56 vs 0.45-5.10) compared with White individuals.

Conclusions

Serum free light chain concentrations differ significantly across racial groups despite exclusion of patients with monoclonal gammopathies and renal dysfunction. Black individuals exhibited consistently higher κ, λ, and κ/λ ratios than White individuals. These findings suggest that application of a single universal reference interval may contribute to racial disparities in interpretation of serum FLC testing and support further multicenter studies to develop population-specific reference intervals that may improve diagnostic accuracy and reduce unnecessary evaluation for LC-MGUS.

Audrey Harris, MD: No relevant conflicts of interest to declare.